TP53 Exon 8 Mutations are Associated with Shorter Survival in Advanced Lung Cancer Patients

2018 ◽  
Author(s):  
Yutao Liu ◽  
Fang Xu ◽  
Yubo Wang ◽  
Qingchen Wu ◽  
Buhai Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients

scholarly journals Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Yanning Wang ◽  
Qianning Zhang ◽  
Chuansheng Chen ◽  
Yuxuan Hu ◽  
Liyun Miao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Overall Survival ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Hazard Ratios

BackgroundIn pivotal immunotherapy trials, the efficacy of immune checkpoint inhibitors as treatments for lung cancer patients with brain metastases remains controversial. The aim of this study was to assess the relative efficacy of immunotherapy versus standard systemic therapy in advanced lung cancer patients with and without brain metastases.MethodsSystematic searches of PubMed, Embase, Cochrane database, and conference proceedings up to Aug 6, 2020 without year and language restrictions. The main outcomes were the overall survival in patients with and without brain metastases measured by hazard ratios, and the difference in efficacy between patients with and without brain metastases was measured by ratio of hazard ratios.ResultsNine eligible randomized controlled trials involving 6241 patients (682 [11%] with brain metastases and 5559 [89%] without brain metastases) were included in the analysis. A survival benefit of immunotherapy was observed for both patients with brain metastases (HR, 0.75; 95%CI, 0.53-0.97; P = .026) and patients without brain metastases (HR, 0.75; 95%CI, 0.67-0.83; P <.001). However, patients without brain metastases benefit more from immunotherapy than patients with brain metastases (HR, 1.37; 95%CI, 1.15-1.63; P = .001). Additionally, subgroup analyses indicated that tumor type affect the efficacy of immunotherapy in patients with brain metastases (HR, 1.04 vs 1.54; interaction, P = .041).ConclusionsImmunotherapy can significantly improve overall survival for advanced lung cancer patients with asymptomatic brain metastases, especially in patients with non-small-cell lung cancer, but the magnitude of benefit is brain metastases dependent.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020206597.

scholarly journals Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: Results of a randomized pilot trial

Cancer ◽  
2014 ◽  
Vol 121 (1) ◽  
pp. 150-158 ◽  
Author(s):  
Hoda Badr ◽  
Cardinale B. Smith ◽  
Nathan E. Goldstein ◽  
Jorge E. Gomez ◽  
William H. Redd
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Family Caregivers ◽  
Psychosocial Intervention ◽  
Pilot Trial ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients

Mitigating differential baseline shifts in locally advanced lung cancer patients using an average anatomy model

2017 ◽  
Vol 44 (7) ◽  
pp. 3570-3578 ◽  
Author(s):  
Mehrsima Abdoli ◽  
Simon R. Van Kranen ◽  
Uros Stankovic ◽  
Maddalena M. G. Rossi ◽  
Jose S. A. Belderbos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Locally Advanced ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Locally Advanced Lung Cancer

Poster - Thur Eve - 20: Serial FDG 4DPET imaging during radiotherapy in advanced lung cancer patients

2012 ◽  
Vol 39 (7Part3) ◽  
pp. 4628-4628
Author(s):  
N Becker ◽  
K Clarke ◽  
V Pekar ◽  
J St-Hilaire ◽  
C Leavens ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document